Novartis Home
At Novartis, we are reimagining medicine
Novartis COVID-19 Information Center
Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.
Annual Reporting 2020
Explore digital versions of the Annual Review 2020, Novartis in Society ESG Report 2020 and previous reports in the Annual Reporting microsite.
From Cancer to Cures
Our new monthly series "Let's Talk About the C Word: From Cancer to Cures" featuring President of Novartis Oncology Dr. Susanne Schaffert, addresses challenging cancer related topics.
Stepping toward a future with cell and gene therapy
Explore this video series about lives that have been touched by this new era of medicine.
Novartis ranks second in 2021 Access to Medicine Index
Novartis maintained its position in the 2021 Access to Medicine Index, leading in its approach to product delivery, while performing strongly across all other areas of the Index.
Our commitment to ethical and responsible use of AI
AI is helping Novartis improve patients’ lives and optimize the healthcare ecosystem. We are committed to deploying AI systems in a transparent and responsible way.
Fortune World’s Most Admired Companies
Novartis rises in the pharmaceutical category of Fortune’s World’s Most Admired Companies list.
Clinical Trials at Novartis
Discover how patients and healthy volunteers get involved in clinical trials to help bring innovative medicines to people.
Our People and Culture
Inspired, Curious and Unbossed are the three pillars of the culture we build to bring out the best in our people.
Our commitment to doing what's right
Novartis is committed to ensuring our associates are empowered to do what’s right. On September 01, 2020, we introduced a new Code of Ethics for Novartis.